Spots Global Cancer Trial Database for vismodegib
Every month we try and update this database with for vismodegib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment | NCT00822458 | Recurrent Child... | vismodegib laboratory biom... pharmacological... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | NCT03767439 | Basal Cell Nevu... | Vismodegib Nivolumab Ipilimumab | 18 Years - | Columbia University | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | NCT01537107 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu... | vismodegib sirolimus positron emissi... computed tomogr... pharmacological... laboratory biom... fludeoxyglucose... | 18 Years - | Mayo Clinic | |
| To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma | NCT02956889 | Carcinoma, Basa... | Vismodegib Radiotherapy | 18 Years - | Istituto Clinico Humanitas | |
| To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma | NCT02956889 | Carcinoma, Basa... | Vismodegib Radiotherapy | 18 Years - | Istituto Clinico Humanitas | |
| Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | NCT01195415 | Recurrent Pancr... Stage IV Pancre... | Gemcitabine Hyd... Laboratory Biom... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas | NCT01556009 | Basal Cell Nevu... Gorlin's Syndro... | Vismodegib Aminolevulinic ... | 18 Years - 75 Years | UCSF Benioff Children's Hospital Oakland | |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | NCT06357988 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Echocardiograph... Radionuclide Im... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | NCT02073838 | Acute Myeloid L... | Ribavirin Vismodegib Decitabine | 18 Years - | Jewish General Hospital | |
| Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | NCT01601184 | Histologically ... Activation of t... | vismodegib Temozolomide | 18 Years - | Centre Leon Berard | |
| Vismodegib for Treatment of Basal Cell Carcinoma | NCT01543581 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | Loma Linda University | |
| Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study | NCT05463757 | Basal Cell Carc... Locally Advance... Metastatic Basa... Gorlin Syndrome Basal Cell Nevu... Carcinoma, Basa... Carcinoma Basal Cell Tumo... Skin Cancer Neoplasm of Ski... Neoplasms, Basa... | Vismodegib Sonidegib | - | Maastricht University Medical Center | |
| Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | NCT01195415 | Recurrent Pancr... Stage IV Pancre... | Gemcitabine Hyd... Laboratory Biom... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | NCT01880437 | Myelodysplastic... | cytarabine vismodegib | 18 Years - | Hoffmann-La Roche | |
| Evaluation of Food Effect on Pharmacokinetics of Vismodegib | NCT01174264 | Malignant Neopl... | Pharmacological... Vismodegib | 19 Years - | National Cancer Institute (NCI) | |
| Vismodegib for Treatment of Basal Cell Carcinoma | NCT01543581 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | Loma Linda University | |
| GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment | NCT00822458 | Recurrent Child... | vismodegib laboratory biom... pharmacological... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Evaluation of Food Effect on Pharmacokinetics of Vismodegib | NCT01174264 | Malignant Neopl... | Pharmacological... Vismodegib | 19 Years - | National Cancer Institute (NCI) | |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | NCT03767439 | Basal Cell Nevu... | Vismodegib Nivolumab Ipilimumab | 18 Years - | Columbia University | |
| Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) | NCT01631331 | Basal Cell Carc... Recurrent Skin ... | vismodegib Mohs surgery | 18 Years - | Stanford University | |
| A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | NCT01878617 | Medulloblastoma | Craniospinal Ir... Cyclophosphamid... Cisplatin Vincristine Vismodegib Pemetrexed Gemcitabine Aerobic Trainin... Neurocognitive ... | 3 Years - 39 Years | St. Jude Children's Research Hospital | |
| Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | NCT01163084 | Prostate Adenoc... Stage IIA Prost... Stage IIB Prost... | Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | NCT01880437 | Myelodysplastic... | cytarabine vismodegib | 18 Years - | Hoffmann-La Roche | |
| GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT00980343 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | vismodegib therapeutic con... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention | NCT02067104 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | University of Arizona | |
| A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas | NCT01815840 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | Hoffmann-La Roche | |
| GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT00980343 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | vismodegib therapeutic con... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma | NCT01201915 | Basal Cell Carc... | Vismodegib | 21 Years - | Genentech, Inc. | |
| Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer | NCT00982592 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | oxaliplatin leucovorin calc... fluorouracil placebo vismodegib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC) | NCT02371967 | Basal Cell Carc... | Vismodegib | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma | NCT03035188 | Basal Cell Carc... | Vismodegib | 18 Years - | SRH Wald-Klinikum Gera GmbH | |
| Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention | NCT02067104 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | University of Arizona | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | NCT04341181 | Cancer Tumors Neoplasms Neoplasia | Alectinib Atezolizumab Avelumab Axitinib Erlotinib Vemurafenib plu... Trastuzumab plu... Trastuzumab emt... Vismodegib Niraparib | 18 Years - | Rigshospitalet, Denmark | |
| VISmodegib for ORbital and Periocular Basal Cell Carcinoma | NCT02436408 | Carcinoma, Basa... | Vismodegib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC) | NCT02371967 | Basal Cell Carc... | Vismodegib | 18 Years - | Hoffmann-La Roche | |
| Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma | NCT01835626 | Locally Advance... Skin Cancer Cutaneous Malig... | Vismodegib Radiation thera... | 18 Years - | University of California, San Francisco | |
| A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma | NCT01898598 | Basal Cell Carc... | Placebo Vismodegib | 18 Years - | Hoffmann-La Roche | |
| Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma | NCT00939484 | Adult Medullobl... | Pharmacological... Vismodegib | 22 Years - | National Cancer Institute (NCI) | |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | NCT02091141 | Neoplasms Solid Tumors Biliary Cancer Salivary Cancer Bladder Cancer | Trastuzumab Pertuzumab Erlotinib Vemurafenib Cobimetinib Vismodegib Alectinib Atezolizumab | 18 Years - | Genentech, Inc. | |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | NCT04341181 | Cancer Tumors Neoplasms Neoplasia | Alectinib Atezolizumab Avelumab Axitinib Erlotinib Vemurafenib plu... Trastuzumab plu... Trastuzumab emt... Vismodegib Niraparib | 18 Years - | Rigshospitalet, Denmark | |
| Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention | NCT02067104 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | University of Arizona | |
| A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | NCT00959647 | Ovarian Cancer Basal Cell Carc... Metastatic Colo... | Vismodegib FOLFOX FOLFIRI Bevacizumab | 18 Years - | Genentech, Inc. | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | NCT05159245 | Advanced Cancer Solid Tumor Haematological ... | Alectinib Cobimetinib Vismodegib Trastuzumab+Per... Entrectinib Atezolizumab Vemurafenib Regorafenib Apalutamide Abemaciclib Selpercatinib Dabrafenib Trametinib Dabrafenib+Tram... Pralsetinib | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | NCT01330173 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Vismodegib Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | NCT01878617 | Medulloblastoma | Craniospinal Ir... Cyclophosphamid... Cisplatin Vincristine Vismodegib Pemetrexed Gemcitabine Aerobic Trainin... Neurocognitive ... | 3 Years - 39 Years | St. Jude Children's Research Hospital | |
| A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC) | NCT02371967 | Basal Cell Carc... | Vismodegib | 18 Years - | Hoffmann-La Roche | |
| NCT Neuro Master Match - N²M² (NOA-20) | NCT03158389 | Glioblastoma, A... | APG101 Alectinib Idasanutlin Atezolizumab Vismodegib Temsirolimus Palbociclib | 18 Years - | University Hospital Heidelberg | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma | NCT01774253 | Pontine Glioma | Vismodegib | 3 Years - 18 Years | Milton S. Hershey Medical Center | |
| SMMART Adaptive Clinical Treatment (ACT) Trial | NCT05238831 | Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre... | Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib | 18 Years - | OHSU Knight Cancer Institute | |
| A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas | NCT01815840 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy | NCT02115828 | Prostate Cancer | Vismodegib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention | NCT02067104 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | University of Arizona | |
| To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | NCT06344052 | Basal Cell Carc... | SP-002 Vismodegib | 18 Years - | Stamford Pharmaceuticals, Inc. | |
| Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma | NCT05561634 | Basal Cell Carc... Radiotherapy; C... | Radiotherapy Observation Vismodegib | 18 Years - | University Hospital, Lille | |
| Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer | NCT01713218 | Pancreatic Aden... | gemcitabine Vismodegib Neoadjuvant che... | 18 Years - | Erasme University Hospital | |
| Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC) | NCT02674009 | Carcinoma, Basa... | Vismodegib | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma | NCT01201915 | Basal Cell Carc... | Vismodegib | 21 Years - | Genentech, Inc. | |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT05538091 | Platinum-Resist... Platinum-Resist... PARP Inhibitor Hedgehog Inhibi... | Vismodegib Atezolizumab | 18 Years - | University of Pittsburgh | |
| Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | NCT02073838 | Acute Myeloid L... | Ribavirin Vismodegib Decitabine | 18 Years - | Jewish General Hospital | |
| Vismodegib for Treatment of Basal Cell Carcinoma | NCT01543581 | Basal Cell Carc... | Vismodegib Placebo | 18 Years - | Loma Linda University | |
| A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage | NCT00887159 | Extensive Stage... Recurrent Small... | Cisplatin Cixutumumab Etoposide Laboratory Biom... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | NCT01367665 | Basal Cell Carc... | vismodegib | 18 Years - | Hoffmann-La Roche | |
| Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma | NCT01835626 | Locally Advance... Skin Cancer Cutaneous Malig... | Vismodegib Radiation thera... | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
